CellaVision — AGM Information 2011

Apr 26, 2011

Bulletin from the Annual General Meeting of CellaVision AB (publ) held on April 26, 2011

The CellaVision Annual General Meeting (AGM) convened earlier today in Lund, April 26 2011, and resolved upon the following:

• Appropriation of profit/loss etc.
• Discharge from liability for the members of the Board of Directors and the President and CEO
• Board of Directors and remuneration
• Incentive program for senior management
• Authorization for the Board of Directors to issue shares, warrants or convertibles
• Amendment of the Articles of Association

More detailed information concerning the resolutions passed at the general meeting of shareholders is available in Swedish only.

CEO Yvonne Mårtensson's address to the meeting is available via the link below.

For mor e information, please contact:

Lars Gatenbeck, Chairman of the Board, CellaVision AB. Tel: +46 70 535 44 44. E-mail: lars.gatenbeck@lifeequity.se Yvonne Mårtensson, CEO, CellaVision AB. Tel: +46 708 33 77 82. E-mail: yvonne.martensson@cellavision.com

About CellaVision

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The analyses often constitute important reference data for fast and correct diagnosis of illnesses, for example of infections and serious cancers. CellaVision's products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In 2010 sales were SEK 132 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund and the company has subsidiaries in the USA, Canada and Japan. The share is listed on the N asdaq, OMX Stockholm, Small Cap list. Read more at www.cellavision.com .

Annual General Meetingin CellaVision 2011

Yvonne Mårtensson, CEO

Introduction

• CellaVision is world leader in a market with large potential, offering automated digital cell morphology
• The hematology analysis market comprises more than 1 billion CBC tests a year – manual differential work equivalent to more than USD 1 billion
• CellaVision's market includes products to about 15,000 laboratories worldwide
• –The market value is estimated to minimum SEK 5 billion
• In a mature market, products will be replaced in a 5 years cycle

Global customer base

• 900 systems mainly in Europe and North America
• Hospital and commercial hematology laboratories
• The hospital demand for efficiency and cost reduction makes automation the obvious choice
• The labor shortage of biomedical scientists is a market driver

Our unique technology adds value

• Efficiencycost reduction and increased productivity
• Proficiencyincreased quality of results
• Connectivitybetween sites; enhanced opportunity for collaboration and sharing of competences

The analyses often constitute important reference data for fast and correct diagnosis of illnesses

Blood

infections, allergies, anemia, and serious blood cancers such as leukemia and lymphoma

Body fluids

infections, inflammations, parasitic diseases and various cancers

42 customers in the Nordic countries

6

Sweden

Network capabilities give staffing flexibility at Karolinska University Hospital, Stockholm

CellaVision in short

• Sales through Sysmex and Beckman Coulter. Direct sales through subsidiaries in the Nordic countries, the US, Canada and Japan
• Headquarters in Lund, Sweden
• 58 employees
• Manufacturing outsourced to Kitron AB, Karlskoga, Sweden
• 18 patented innovations
• Competition: Manual microscopy First competitor product launched in July 2010 in the US

CellaVision's product offering

Analyzers

• CellaVision® DM96
• CellaVision® DM1200

Optional application for body fluids analysis

CellaVision® Body Fluid Application

Software for networking and remote access

CellaVision® Remote Review Software

Software for proficiency testing and education

CellaVision® Competency Software

Consumables, accessories, service

Financial performance 2001–2010

Sales per geographical segment

Achievements in 2010

Another year of profit and strong growth

• Net sales rose by 21 % to SEK 131.6 million (109.0).
• Operating profit for the year was SEK 13.9 million (14.8).
• Profit after tax was SEK 38.3 million (27.7)
• Earnings per share for the year were SEK 1.61 (1.16).
• Cash and cash equivalents amounted to SEK 35.8 million (22.0) at year end.
• CellaVision strengthens distribution network in the US by entering an agreement with Beckman Coulter.
• CellaVision and Sysmex enhance partnership by signing a global distribution agreement.
• CellaVision was listed on Nasdaq OMX Stockholm Small Cap on May 31, 2010.
• Tredje AP-fonden new major shareholder in CellaVision.
• Unilabs streamlines laboratory operations with analyzers from CellaVision.

Financial objectives

CellaVision's target is to increase sales by an average of at least 15 % per year over an economic cycle with an operating margin of more than 15 %.

2010

• Growth: 21 %
• Operating margin: 10.6 %

Financial report Q1, 2011 in summary

Strong start to the year

• Net sales rose by 45 % to SEK 30.6 million (21.1).
• Operating profit was SEK 2.5 million (-4.4).
• Profit after tax was SEK 0.1 million (-4.7)
• Earnings per share were SEK 0.00 (-0.20).
• Cash and cash equivalents at the end of the quarter were SEK 40.2 million (18.0).

Events 2011

• CellaVision reinforced its management team with StefanBengtsson as Chief Operating Officer.
• CellaVisions new product concept for hospital networks enters the evaluation phase
• Smaller laboratories with limited resources may now digitize their samples and have the analysis performed at a laboratory where a CellaVision instrument is located.
• Complements the company's current digital cell morphology products that are marketed to laboratories with large and medium-size workloads.
• The concept will be evaluated by a number of hospital laboratories this spring for the company to decide and further develop the final product during the latter part of 2011.

CellaVision going forward

Hematology Business

• Continue global market penetration in Europe, the USand Asia, with focus on North America and Japan.
• Product development projects with the aim of strengthening the analyzers' customer values through increased functionality and more possible applications.
• Increased focus on product supply. Adapting our product development and production to the growing demand.

Shareholders

S h h l d a r e o e r	h # s a r e s	%
S i f l I d i f d t t t e s e n n u s r o n e n	3 8 2 5 7 5 7 , ,	1 0 5
M l l i F ö l i A B t t e a c a r v a n n g s	2 3 9 6 7 7 7 , ,	1 1 6
å C h i F h b l t r s e r r a e u s m o a g	2 4 0 0 0 0 0 , ,	1 0 1 ,
L i f k i A B S k d i ö ä r s r n g s a n a v	1 6 2 6 7 8 3 , ,	6 8 ,
f T d j A P d r e e o n e n -	1 6 0 6 2 0 7 , ,	6 7 ,
L i d k l l H l d i A B n e u e n o n g	9 6 3 8 6 7 ,	4 0 ,
S f j ä A P d t t e o n e n -	6 4 4 4 1 6 ,	2 7 ,
U i n o n e n	4 9 1 6 3 4 ,	2 1 ,
F k i k i b l A ö ä t t, r s r n g s a e o a g e a n a v z P i e n s o n	4 8 9 6 8 9 ,	2 0 ,
f P i H l h A B t z e r e a	4 2 9 6 1 1 ,	1 8 ,
O h t e r	8 8 3 6 8 4 7 , ,	3 2 7
T O T A L	2 3 8 5 1 5 4 7 , ,	1 0 0 0

The share

• Listed at NASDAQ OMX Stockholm, Small Cap May 31, 2010.
• Ticker symbol: CEVI
• Market Cap: ~290 MSEK
• More than 1,600 shareholders

Share price development sinceJan 1, 2009

For more information, please visitwww.cellavision.com

blog.cellavision.com

App: CellAtlas